Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.7K Buy
15
+2
+15% +$198 ﹤0.01% 203
2026
Q1
$1.22K Hold
13
﹤0.01% 210
2025
Q4
$1.28K Buy
13
+8
+160% +$774 ﹤0.01% 205
2025
Q3
$424 Sell
5
-2
-29% -$158 ﹤0.01% 327
2025
Q2
$477 Buy
7
+1
+17% +$63 ﹤0.01% 282
2025
Q1
$363 Buy
6
+4
+200% +$279 ﹤0.01% 302
2024
Q4
$138 Hold
2
﹤0.01% 295
2024
Q3
$132 Hold
2
﹤0.01% 339
2024
Q2
$121 Sell
2
-1
-33% -$57 ﹤0.01% 308
2024
Q1
$171 Hold
3
﹤0.01% 258
2023
Q4
$188 Hold
3
﹤0.01% 239
2023
Q3
$173 Buy
+3
New +$189 ﹤0.01% 240
2023
Q1
Sell
-2
Closed -$156 255
2022
Q4
$161 Hold
2
﹤0.01% 243
2022
Q3
$0 Hold
2
﹤0.01% 235
2022
Q2
$151 Buy
+2
New +$152 ﹤0.01% 243
2022
Q1
Sell
-1
Closed -$73 254
2021
Q4
$73 Buy
+1
New +$67 ﹤0.01% 364
2021
Q3
Hold
0
359
2021
Q2
Hold
0
347

Other funds holding INCY

WestEnd Advisors's INCY Position: Q2 2026 in Review

WestEnd Advisors increased its Incyte (INCY) stake by 15% in Q2 2026, buying an estimated $198 and bringing the position to 15 shares worth $1.7K. The position accounts for ﹤0.01% of the portfolio, ranked #203.

WestEnd Advisors first reported a position in INCY in Q4 2021 and has held it in 16 quarters since. 859 funds tracked by Wall St. Rank hold INCY as of Q2 2026.

  • WestEnd Advisors held 15 shares of Incyte worth $1.7K as of Q2 2026.
  • WestEnd Advisors bought 2 Incyte shares in Q2 2026, an estimated $198.
  • Incyte made up ﹤0.01% of WestEnd Advisors's portfolio in Q2 2026, its #203 holding.
  • WestEnd Advisors first reported a position in Incyte in Q4 2021 and has held it in 16 quarters since.
  • 859 funds tracked by Wall St. Rank held Incyte as of Q2 2026.

Based on WestEnd Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.